SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Canada-based Avivagen Inc.'s (VIV:TSX.V) proprietary OxC-beta™ Livestock premix for livestock feeds is a non-antibiotic means of maintaining optimal health and growth. Its use in Asia has been growing rapidly, and Avivagen recently announced a partnership with CSA Animal Nutrition for sales and distribution of the product in the United States. The U.S. market comprises 20% of the worldwide livestock feed market.
Company mentioned: Avivagen Inc.
"We're very excited to be entering into this important relationship that will bring OxC-beta to this crucial market and allow for the sale of OxC-beta within the U.S.," Kym Anthony, chairman and interim CEO of Avivagen, stated.
"With CSA's extensive technical experience and relationships and ability to access the U.S. livestock and poultry markets, CSA represents a strong partner for Avivagen. The timing is good given the regulatory process in the U.S. is now completed and we look to add sales and distribution networks in new markets to significantly drive our sales," Anthony added.
A panel of experts following specific government guidelines determined that OxC-beta qualifies as self-determined "Generally Recognized as Safe" (GRAS) in U.S., thereby clearing its way for distribution within the country.
CSA's agreement with Avivagen specifies minimum performance targets for the first three years (the agreement can be found at www.SEDAR.com), which if met will greatly enhance Avivagen's sales volumes going forward.
In addition to the U.S., OxC-beta is available for sale in the Philippines, Taiwan, New Zealand and Thailand.
Continue reading this article: Large US Market Now Open to Livestock Feed Antibiotic Replacement
About Streetwise Reports
Streetwise Reports shares investment ideas in many sectors. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen.
The full disclosure is provided at the article's end: Large US Market Now Open to Livestock Feed Antibiotic Replacement